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INTRODUCTION
Children account for 10-15% of the global tuberculosis (TB) disease burden, 1 resulting in an estimated 550,000 to 1,000,000 cases yearly, and an estimated 80,000 deaths in HIV-uninfected children globally in 2013. 2, 3 Substantial resources are being invested in addressing the global problem of multidrug-resistant (MDR)-TB, defined as Mycobacterium tuberculosis resistant to isoniazid (INH) and rifampicin (RIF), however limited attention has been given to TB that is INH-resistant but RIF-susceptible (HRRS-TB).
The 2014 Global TB Report of the World Health Organization (WHO) estimated that HRRS-TB represented on average 9.5% of all cases, including 8.1% of new cases and 14.0% of previously treated cases, with substantial regional variation. 2 Data on HRRS-TB prevalence in children is limited. Recent estimates suggest that 12.1% of incident TB cases in children globally were INH-resistant in 2010, with many of these likely being HRRS depending on the setting. 4 In Cape Town, South Africa, ongoing enhanced hospital-based surveillance showed that between 2003-2011, 5.1-7.7% of children <13 years with culture-confirmed TB had HRRS-TB. 5 With a high early bactericidal activity, INH is responsible for a rapid initial reduction in mycobacterial burden, potentially decreasing patients' infectiousness, hastening clinical improvement, 6, 7 and protecting against resistance development in other drugs in the regimen. 7 Current adult and paediatric guidelines recommend treating HRRS-TB with 6-12 months of RIF, pyrazinamide (PZA), and ethambutol (EMB), with the addition of a fluoroquinolone for extensive disease. [8] [9] [10] [11] [12] Evidence for these recommendations is low quality, and no controlled trials have evaluated regimens for HRRS-TB in adults or children. 13, 14 A systematic review and meta-analysis showed variable but substantial rates of treatment failure, relapse, and acquired drug resistance in adults with HRRS-TB . 15 Children with HRRS-TB may be at particular risk for poor treatment outcomes as they may be treated with a standard 3 drug intensive phase containing RIF, INH, and PZA, (RHZ) which is likely inadequate in the context of INH resistance. The clinical presentation, treatment, and outcomes of children with HRRS-TB are poorly described, 16 and more data on this important TB disease entity in children is needed.
The Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA), a new molecular diagnostic tool for rapid detection of TB and RIF resistance in clinical specimens, 17 is increasingly used globally for TB diagnosis, including in children. 18 19 The inability to test for INH resistance means the roll-out of Xpert MTB/RIF may have important implications for the detection and management of HRRS-TB in children, since this entity would be under-detected using Xpert MTB/RIF only.
This study aimed to characterize the clinical presentation, treatment and clinical and microbiological outcomes in children with culture-confirmed HRRS-TB; we also investigate factors associated with poor treatment outcomes.
STUDY POPULATION AND METHODS

Study Design
Retrospective hospital-based cohort study.
Setting and patient management
This study was undertaken at three hospitals in the Western Cape Province, South Africa, where the TB notification rate was 954.1 cases per 100,000 population in 2010. 20 Tygerberg Children's Hospital (TCH) is a large provincial referral centre for children, where, as part of ongoing surveillance, a database of all routine cultureconfirmed TB in children is maintained. Brooklyn Hospital for Chest Diseases (BHCD) is a specialized TB hospital which cares for children with drug-resistant-TB, TB meningitis (TBM) and children who need social support. Brewelskloof Hospital (BKH) is a regional TB hospital managing the long-term treatment of drug-resistant TB patients, including children.
Mycobacterial cultures were routinely performed at the South Africa National Health Laboratory Service (NHLS) laboratories, according to a standardized protocol using 
Study population
Children were included if they were <13 years of age, routinely diagnosed or managed at any of the three study hospitals, and had a culture from any clinical specimen positive for M. tuberculosis, with DST demonstrating INH-resistance and RIF-susceptibility, between January 1, 2006 through December 31, 2011.
Data collection
Potentially eligible patients were identified from the ongoing routine surveillance at the 3 hospitals. For identified patients, medical records were reviewed and relevant data extracted using a standard form. Mantoux tuberculin skin test (TST) results were considered positive if ≥5mm in HIV-infected children and ≥10mm in HIVuninfected children. Previous treatment was considered receipt of TB medications for disease or preventive therapy. TB was classified according to site of disease as pulmonary, extrapulmonary, or both, and the severity of disease was categorized according to consensus classification of TB disease severity in children. 21 Weight-for-age Z-scores (WAZ) were calculated using the 1990 British growth reference, as WHO growth references only include children up to 10 years of age. 22 TB treatment outcomes were classified as either "Favourable", which included cure, probable cure, and treatment completion, 23 or "Unfavourable". 23 
RESULTS
Seventy-two children were included; sixty (83%) from TCH, 9 (13%) from BHCD, and In univariable analysis, no characteristics were associated with unfavourable outcome; older age (p=0.008), documented previous TB treatment (p=0.023) and severe PTB (p=0.018) were associated with positive follow-up cultures at ≥2 months after treatment initiation (table 4) .
DISCUSSION
In this large cohort of children with culture-confirmed HRRS-TB, overall clinical outcomes were good. However a number of children had prolonged culture positivity and treatment failure, emphasizing the need for additional attention to clinical management of this subgroup of children with TB. To our knowledge, the largest report to date is a single case series of 26 children treated for HRRS-TB in New York between 1961 and 1972. 16 One child died, but the remaining patients completed treatment with good outcomes. The relevance of that study to current practice is limited, as the majority were treated without RIF or PZA, and received variable three and four drug combinations of INH, para-aminosalicylic acid (PAS), streptomycin, RIF, EMB, ethionamide and cycloserine. 16 The cohort we report here provides data on the clinical presentation, treatment, and outcomes of a substantial number of children with HRRS-TB, which reflects currently available drug regimens in global settings.
In our study, just over 60% of children had a known potential TB source case, consistent with children with culture-confirmed TB in our context. 5 However, only 24% of the potential source cases had confirmed HRRS-TB. The potential MDR-TB source cases reported in eight patients may reflect infection of the child with HRRS M.tuberculosis prior to the source case's acquisition of additional RIF resistance.
The majority of the adult source cases had unknown drug-susceptibility. Clinical records however frequently indicated that source cases were retreatment cases or were on an injectable (indicating a retreatment regimen or MDR-TB); this was difficult to quantify, but it is likely that a substantial portion of those source cases with unknown drug-susceptibility were in fact HRRS-TB. The high proportion of source cases with unknown drug-susceptibility may have contributed to delayed initiation of an appropriate treatment regimen in child contacts. In keeping with this concern, 36% of children in our cohort were initially started on a 3-drug intensive phase with RHZ. However, the presence of a known source case was not a risk factor for having an unfavourable outcome or prolonged culture positivity. With the roll-out of Xpert MTB/RIF test as the initial diagnostic test for TB, information regarding the INH resistance of source cases is likely to become less available. This has important implications for the prophylaxis and treatment of children exposed to adults with HRRS-TB.
As would be expected for hospital-based cohorts, children in this study had significant clinical disease with 50% being underweight (WAZ<-2), 60% of those with PTB having severe disease, and 45% of those tested being AFB sputum smearpositive. The proportion with severe PTB in our cohort is comparable to children with culture-confirmed MDR-TB from the same setting (45.9% with severe chest radiograph findings), 24 although the case definitions differed slightly between the two studies. The high proportion of severe disease in our study may reflect delays in presentation and initiation of appropriate treatment.
Treatment regimens were highly variable and difficult to classify. The long treatment duration was likely related to the observed severity of disease, as well as a conservative approach taken given concern about potentially acquired resistance during periods of inadequate treatment. However, the duration of treatment with a regimen appropriate to HRRS-TB was within the recommended range (6-12 months) for most patients.
A substantial risk of treatment failure and acquired drug resistance in adults with HRRS-TB has been reported in adults receiving standard short course chemotherapy and in those treated with RHZE. 25, 26 Conclusions about the most appropriate regimen or treatment duration for HRRS-TB in children should be drawn cautiously from our study, which was observational and had no control arm.
Children treated with a fluoroquinolone may have done equally well with a less intensive regimen such as 6RHZE, and shorter treatment durations may have been as effective. However, given increasing concerns about low RIF exposures in children, 27, 28 and a growing body of evidence regarding fluoroquinolone safety in children, 29, 30 the addition of a fluoroquinolone may be reasonable. It is important to note that children in this cohort treated with the long durations and fluoroquinolonecontaining regimens had good outcomes, despite having severe disease.
Microbiological outcomes in children treated for TB have not been well described. A substantial proportion of children in our cohort had positive cultures at one and two months after initiating TB treatment; of 37 patients with at least one follow-up culture, 10 (27%) had positive cultures at ≥2 months. In a cohort of children with MDR-TB in our setting, 9 of 41 (22%) with bacteriological confirmation remained culture-positive at 2 months. 29 The three patients with failed treatment and prolonged culture positivity (table 2) are particularly concerning. Poor adherence cannot be ruled out as a cause of the prolonged culture-positivity, however this delayed treatment response is unusual in cases with drug-susceptible TB in our experience. The child with acquisition of rifampicin-resistance and progression of disease on inadequate treatment has been described in detail elsewhere, 31 and highlights the potential risk for children with HRRS-TB inadequately treated. Our cohort received highly individualized treatment; in settings where there is limited access to culture and DST and children with HRRS-TB may receive standard short-course regimens, outcomes may not be as good. We suspect the four patients treated with standard drugsusceptible TB treatment in the months prior to their HRRS-TB episode likely had HRRS-TB in their first episode, which then relapsed (table 2); this provides additional evidence of poor treatment response.
HRRS-TBM may be particularly problematic to treat, due to poor penetration of RIF and EMB into CSF, and some adult data suggest a worse outcome compared to drug-susceptible TBM. 32 The favourable outcomes in children with HRRS-TBM in our cohort may be related to the empiric regimen for TBM in use in our setting, which includes higher doses of INH and RIF, and ethionamide, which has excellent CSF penetration. The majority of children with TBM in this cohort also received a fluoroquinolone with or without terizidone, both of which have good CSF penetration.
Fluoroquinolones are being investigated for their potential to improve TBM outcomes in adults. 33 In univariable analysis there were no statistically significant associations with unfavourable treatment outcomes. However, older age, previous treatment, and severe PTB were associated with culture positivity at ≥2 months' treatment. We hypothesize that this is driven primarily by disease severity. Older age was associated with severe PTB, and older children have a well-described higher risk of developing adult-type disease. 34 Previous treatment was also associated with severe TB and may be a marker of failed previous treatments. We explored these associations using multivariable logistic regression; however this analysis was limited by the small sample size, associations between all the included variables, and numeric challenges including zero-cells.
A limitation of the study is the retrospective design. There was limited information on adherence, which may have impacted on clinical and microbiologic outcomes. The lack of a drug-susceptible TB control group prohibited us from concluding whether outcomes in our cohort significantly differed from children with drug-susceptible TB.
There may be limited generalizability of our findings to children treated in the community, where less severe TB would be expected and treatment responses may be more favourable given lower organism burden.
CONCLUSIONS
Although the impact of treatment regimens and treatment outcomes in this cohort should be interpreted with caution, our data has begun to fill an important gap in knowledge on the treatment of HRRS-TB in children. This is the largest study describing treatment and outcomes of HRRS-TB in children. As there are implications for preventive therapy and treatment in children exposed to and diseased due to HRRS-TB, the relevance of knowing the INH resistance pattern of the child and source case needs to be considered with the broad roll-out of Xpert MTB/RIF. Our data raises sufficient concern to warrant further evaluation of the most appropriate treatment of HRRS-TB in children. 
